(Q37672591)

21 August 2017

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study (English)

1 reference

21 August 2017

0 references

Stephanie C Steinberg

1

1 reference

21 August 2017

Richard J Faris

2

1 reference

21 August 2017

Cyril F Chang

3

1 reference

21 August 2017

Andrew Chan

4

1 reference

21 August 2017

Mark A Tankersley

5

1 reference

21 August 2017

language of work or name

1 reference

1 January 2010

1 reference

Clinical Drug Investigation

21 August 2017

1 reference

21 August 2017

30

1 reference

21 August 2017

2

1 reference

21 August 2017

89-100

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 August 2017

1 reference

https://api.crossref.org/works/10.2165%2F11533330-000000000-00000

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533330-000000000-00000

Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533330-000000000-00000

Comparing Sources of Drug Data about the Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533330-000000000-00000

The language of medication-taking

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533330-000000000-00000

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533330-000000000-00000

Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil

21 January 2018

1 reference

12 December 2020

Compliance, adherence, and the treatment of multiple sclerosis

1 reference

12 December 2020

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

1 reference

12 December 2020

Validity of a prescription claims database to estimate medication adherence in older persons

1 reference

12 December 2020

Cost and health related quality of life consequences of multiple sclerosis

1 reference

12 December 2020

Medication adherence and persistence: a comprehensive review

1 reference

12 December 2020

Improving compliance with interferon-beta therapy in patients with multiple sclerosis

1 reference

12 December 2020

Factors that influence adherence with disease-modifying therapy in MS.

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis

1 reference

12 December 2020

Hypertension and current issues in compliance and patient outcomes

1 reference

12 December 2020

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

1 reference

12 December 2020

A framework for planning and critiquing medication compliance and persistence research using prospective study designs

1 reference

12 December 2020

Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses

1 reference

12 December 2020

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

1 reference

12 December 2020

Adherence to Medication

1 reference

12 December 2020

Immunologic therapy for relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).

1 reference

12 December 2020

Self reported stressful life events and exacerbations in multiple sclerosis: prospective study

1 reference

12 December 2020

Cost of managing an episode of relapse in multiple sclerosis in the United States

1 reference

12 December 2020

Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome

1 reference

12 December 2020

Estimating medication persistency using administrative claims data.

1 reference

12 December 2020

Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients

1 reference

12 December 2020

Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D.

1 reference

12 December 2020

Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis

1 reference

12 December 2020

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

1 reference

12 December 2020

Chronic disease score as a predictor of hospitalization

1 reference

12 December 2020

The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec

1 reference

12 December 2020

Validation of pharmacy records in drug exposure assessment

1 reference

12 December 2020

Interferon-β in the treatment of relapsing–remitting multiple sclerosis

1 reference

12 December 2020

Quality of life and cost of multiple sclerosis

1 reference

12 December 2020

A checklist for medication compliance and persistence studies using retrospective databases.

1 reference

12 December 2020

Multiple sclerosis relapses: a multivariable analysis of residual disability determinants

1 reference

12 December 2020

Long-term interferon-beta treatment for multiple sclerosis

1 reference

12 December 2020

Factors leading patients to discontinue multiple sclerosis therapies

1 reference

12 December 2020

10.2165/11533330-000000000-00000

Identifiers

DOI

1 reference

21 August 2017

1 reference